Center for Medicine in the Public Interest

The Center for Medicine in the Public Interest (CMPI) is a non-profit medical issues research group.[2] It was founded by the "free-market think tank" Pacific Research Institute.[3] CMPI's research agenda deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation.

Center for Medicine in the Public Interest
AbbreviationCMPI
Typenon-profit medical issues research group think tank
HeadquartersNew York City, United States
Key people
  • Robert Goldberg
  • Gad Berdugo
  • Fred Goodwin
  • Steven Sammut
  • Michael Tew
  • Mark Thornton
  • Michael Weber
Revenue (2014)
$353,000[1]
Expenses (2014)$373,744[1]
Websitecmpi.org

CMPI is a 501(c)3 organization and as such is not permitted to devote a substantial part of its activity to lobbying. Its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States,[4] and restrictions on advertising in the European Union.[5] The Economist Intelligence Unit has written that the organisation generally takes a pro-drug industry viewpoint.[6]

Issues

Universal healthcare

CMMPI is a strong opponent of universal healthcare and favors a free-market approach to health care policy. The center created website called BigGovHealth.org to tell the stories of people who faced difficulties with the health care systems in Europe and Canada. The site also includes interviews with health policy experts in Europe and Canada.[7]

Drug imports

The group opposes the importation of drugs in order to lower prices in the United States, arguing in part that Canadian pharmaceutical companies' products are dangerous because they are not regulated by the FDA but by foreign government agencies.[8]

Personnel

CMPI was founded by Peter Pitts, former FDA Associate Commissioner for External Relations under the Bush administration, and Dr. Robert Goldberg, former fellow at the Manhattan Institute.[9]

CMPI Senior Fellows include:

  • Marc Siegel
  • Doug Badger
  • John F. P. Bridges
  • Jacob Arfwedson

Funding

Funders include PhRMA and Pfizer.[10]

Reports

CMPI has published studies on the value of new cancer drugs, the cost-effectiveness of certain Alzheimer's treatments, evidence-based medicine, and drug counterfeiting.[11]

References
  1. "Center for Medicine in the Public Interest" (PDF). Foundation Center. Retrieved 23 March 2017.
  2. Herper, Matthew (2007-07-25). "The Nissen Doctrine". Forbes. Retrieved 2008-01-14.
  3. Lee Fang (Nov 18, 2009). "Exclusive: Attacks On Health Reform Orchestrated By Yet Another Shadowy Corporate Front Group — 'CMPI'". Center for American Progress. Retrieved 19 November 2009.
  4. Goldberg, Robert (2006-12-25). "HillaryCare Comes Back". The Weekly Standard. News America Incorporated. Retrieved 2008-01-14.
  5. Pitts, Peter J. (2006-04-12). "Power to the Patients". Wall Street Journal. Retrieved 2008-01-14.
  6. "USA healthcare: FDA centenary prompts politicking". Economist Intelligence Unit. Economist Group. 2006-07-05. Retrieved 2008-01-14.
  7. https://www.politico.com/story/2008/07/site-attacks-single-payer-health-care-011570
  8. https://thehill.com/opinion/healthcare/426615-proposed-drug-importation-bill-would-expose-americans-to-counterfeit-meds
  9. Jason Lee Miller (2008-08-01). "Are Google Results Hazardous To Your Health?". WebProNews. iEntry, Inc. Archived from the original on 2008-01-12. Retrieved 2008-01-14.
  10. http://www.politico.com/news/stories/0708/11570.html
  11. Laurie Sullivan (2006-06-13). "Pharmaceuticals Slowly Adopting RFID To Protect Prescription Drug Supplies". Information Week. CMP Media LLC. Retrieved 2008-01-14.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.